Diabetes patients with CKD on bardoxolone methyl show higher heart risk

01/2/2014 | Healio (free registration)

Data on 2,185 patients with type 2 diabetes and stage 4 chronic kidney disease revealed those who received bardoxolone methyl had a higher incidence of cardiovascular-related death, heart failure and hospitalization compared with those taking a placebo. The drug was also associated with increased incidence of nonfatal myocardial infarction and nonfatal stroke in patients, researchers reported in the New England Journal of Medicine.

View Full Article in:

Healio (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX